Cargando…

COVID-19: Mechanisms of Vaccination and Immunity

Vaccines are needed to protect from SARS-CoV-2, the virus causing COVID-19. Vaccines that induce large quantities of high affinity virus-neutralizing antibodies may optimally prevent infection and avoid unfavorable effects. Vaccination trials require precise clinical management, complemented with de...

Descripción completa

Detalles Bibliográficos
Autores principales: Speiser, Daniel E., Bachmann, Martin F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7564472/
https://www.ncbi.nlm.nih.gov/pubmed/32707833
http://dx.doi.org/10.3390/vaccines8030404
_version_ 1783595722881368064
author Speiser, Daniel E.
Bachmann, Martin F.
author_facet Speiser, Daniel E.
Bachmann, Martin F.
author_sort Speiser, Daniel E.
collection PubMed
description Vaccines are needed to protect from SARS-CoV-2, the virus causing COVID-19. Vaccines that induce large quantities of high affinity virus-neutralizing antibodies may optimally prevent infection and avoid unfavorable effects. Vaccination trials require precise clinical management, complemented with detailed evaluation of safety and immune responses. Here, we review the pros and cons of available vaccine platforms and options to accelerate vaccine development towards the safe immunization of the world’s population against SARS-CoV-2. Favorable vaccines, used in well-designed vaccination strategies, may be critical for limiting harm and promoting trust and a long-term return to normal public life and economy.
format Online
Article
Text
id pubmed-7564472
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-75644722020-10-26 COVID-19: Mechanisms of Vaccination and Immunity Speiser, Daniel E. Bachmann, Martin F. Vaccines (Basel) Review Vaccines are needed to protect from SARS-CoV-2, the virus causing COVID-19. Vaccines that induce large quantities of high affinity virus-neutralizing antibodies may optimally prevent infection and avoid unfavorable effects. Vaccination trials require precise clinical management, complemented with detailed evaluation of safety and immune responses. Here, we review the pros and cons of available vaccine platforms and options to accelerate vaccine development towards the safe immunization of the world’s population against SARS-CoV-2. Favorable vaccines, used in well-designed vaccination strategies, may be critical for limiting harm and promoting trust and a long-term return to normal public life and economy. MDPI 2020-07-22 /pmc/articles/PMC7564472/ /pubmed/32707833 http://dx.doi.org/10.3390/vaccines8030404 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Speiser, Daniel E.
Bachmann, Martin F.
COVID-19: Mechanisms of Vaccination and Immunity
title COVID-19: Mechanisms of Vaccination and Immunity
title_full COVID-19: Mechanisms of Vaccination and Immunity
title_fullStr COVID-19: Mechanisms of Vaccination and Immunity
title_full_unstemmed COVID-19: Mechanisms of Vaccination and Immunity
title_short COVID-19: Mechanisms of Vaccination and Immunity
title_sort covid-19: mechanisms of vaccination and immunity
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7564472/
https://www.ncbi.nlm.nih.gov/pubmed/32707833
http://dx.doi.org/10.3390/vaccines8030404
work_keys_str_mv AT speiserdaniele covid19mechanismsofvaccinationandimmunity
AT bachmannmartinf covid19mechanismsofvaccinationandimmunity